The aberrant function of the SEC61A1 protein has been implicated in various human cancers, including head, lung, prostate, and glioblastoma [12–15], and has been targeted as a therapeutic option in multiple myeloma [10]. This evidence concerns the gene SEC61A1 and cancer.